Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 11/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7773376 | 0.81 | SMPD1 (0.38) | SMPD1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL6883229 | 0.81 | SMPD1 (0.38) | SMPD1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL6892063 | 0.81 | SMPD1 (0.38) | SMPD1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL5376060 | 0.81 | SMPD1 (0.38) | SMPD1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL2058036 | 0.74 | SMPD1 (0.38) | SMPD1TSHRFDPSGGPS1 | |
| SCHEMBL8472572 | 0.74 | TSHR (0.44) | SMPD1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL28654057 | 0.73 | SMPD1 (0.35) | SMPD1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL2058259 | 0.73 | SMPD1 (0.37) | SMPD1TSHRFDPSGGPS1 | |
| SCHEMBL1030960 | 0.72 | FDPS (0.37) | SMPD1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL8756198 | 0.72 | SMPD1 (0.42) | SMPD1FDPSGGPS1CES2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024489-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | INSTITUT PASTEUR (FR) | 2024-01-25 | — | — | US | claimed |
| EP-4247828-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | Institut Pasteur (FR) | 2023-09-27 | — | — | EP | claimed |
| CN-116601163-A | Protected disaccharides, methods for their preparation, their use in the synthesis of zwitterionic oligosaccharides and conjugates thereof | 巴斯德研究所 | 2023-08-15 | — | — | CN | claimed |
| WO-2022106703-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | INSTITUT PASTEUR (FR) | 2022-05-27 | — | — | WO | claimed |
| EP-2049689-B1 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | BI WANLI (US) | 2011-12-21 | — | — | EP | claimed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| CN-111330016-B | Antibody Drug Conjugates (ADCs) that bind 158P1D7 protein | 艾更斯司股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | AGENSYS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-1412346-B1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2005-03-09 | — | — | EP | disclosed |
| US-6280897-B1 | GENERATION OF ACID WITH ACTINIC RADIATION | KABUSHIKI KAISHA TOSHIBA (JP) | 2001-08-28 | — | — | US | disclosed |
| US-6271370-B1 | REACTING 2',3'-O-ALKYLIDENE .BETA.-FURANOSYL HALIDE COMPOUND WITH HETEROCYCLE HAVING RING NITROGEN CAPABLE OF FORMING COVALENT BOND WITH ANOMERIC CARBON OF FURANOSE OR FURANOSE ANALOG IN DIMETHYL SULFOXIDE IN PRESENCE OF STRONG BASE | PFIZER INC | 2001-08-07 | — | — | US | disclosed |
| EP-1052264-A2 | Process for the synthesis of nucleoside analogs | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| US-6071670-A | PHOTORESIST RESIN COMPRISING PHOTOACID GENERATING COMPOUND AND AN ACID HYDROLYZABLE OLIGOMER HAVING ALICYCLIC OR POLYCONDENSED AROMATIC BACKBONE; ALKALI DEVELOPMENT WITH HIGH RESOLUTION, DRY ETCH RESISTANCE | KABUSHIKI KAISHA TOSHIBA (JP) | 2000-06-06 | — | — | US | disclosed |
| US-5932391-A | CONTAINING AN ACYCLIC COMPOUND WHICH IS A VINYL POLYMERBEING LIGHT ABSORBENT | KABUSHIKI KAISHA TOSHIBA (JP) | 1999-08-03 | — | — | US | disclosed |
| US-5863699-A | FORMS A PATTERN THROUGH LIGHT-EXPOSURE WITH EITHER ARGON FLUORIDE OR FLUORINE EXCIMER LASERS, COMPRISES A COMPOUND HAVING EITHER AN ACID-DECOMPOSABLE OR ACID-CROSSLINKABLE GROUP | KABUSHIKI KAISHA TOSHIBA (JP) | 1999-01-26 | — | — | US | disclosed |
| EP-0463470-A2 | Process for the preparation of a fluorotetrahydrofuranone derivative | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | SMPD1 1760/4885TSHR 2706/4885THRB 2976/4885 |
| US-20240024489-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | SI, DAD1, FUT5 | SMPD1 137/4885TSHR 3240/4885THRB 4149/4885 |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, CA12, H1-10 | SMPD1 366/4885TSHR 2385/4885THRB 1052/4885 |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | TMED10, CD44, CA12 | SMPD1 547/4885TSHR 3281/4885THRB 3416/4885 |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, ARID2, DYNLL2 | SMPD1 1586/4885TSHR 3069/4885THRB 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.